Use of Smoking Cessation Aids in a Convenience Sample of PLHIV in a Canadian Tertiary Care Clinic
Blake Linthwaite1, Joseph Cox1, 2, Marina B. Klein1, 2, Hansi Peiris1, Syim Salahuddin1, 3, Jean-Pierre Routy1, 2, Bertrand Lebouché1, 2, Marie-Josée Brouillette1, 2, Jason Szabo1, Andreas Giannakis1, Roger LeBlanc1, Sean Gilman1, 4, Cecilia T. Costiniuk1, 2, *
Identifiers and Pagination:Year: 2019
First Page: 1
Last Page: 6
Publisher Id: TOAIDJ-13-1
Article History:Received Date: 01/11/2018
Revision Received Date: 16/12/2018
Acceptance Date: 28/12/2018
Electronic publication date: 29/1/2019
Collection year: 2019
open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Tobacco smoking is among the most significant predictors of cardiovascular disease and lung cancer in People Living with HIV (PLHIV). Smoking rates in this population are high, necessitating more effective smoking cessation strategies. We conducted a descriptive analysis of tobacco-related clinical and sociodemographic characteristics of smokers at a tertiary care HIV clinic in Montreal and an exploratory analysis of smoking cessation methods in order to identify potential areas of improvement in the clinic’s approach to smoking cessation.
A convenience sample of patients completed a 10-minute questionnaire on tobacco-related behaviours and outcomes. Use of smoking cessation methods was compared using McNemar’s exact test with a Bonferroni correction for multiple testing (p<0.01 considered significant).
Seventy-two PLHIV participated. Two-thirds of our total participants were interested in quitting within six months, but the use of effective cessation strategies was low, particularly for counseling and oral therapy. Overall, oral therapy (e.g. varenicline) (16.7%) and counseling for cessation (5.6%) were used less than nicotine patches (50.0%) or ‘other’ methods (50.0%), which included abstinence and nicotine gum (p<0.001).
Despite a small and potentially unrepresentative sample of HIV positive tobacco smokers at our clinic, this study could help guide further research aiming to determine and address barriers to smoking cessation and access to effective smoking cessation aids in PLHIV. Future studies might consider factors that affect motivation to quit, such as co-morbid mental health and substance use disorders, or the attitudes of HIV healthcare providers.
Tobacco smoking is among the most significant predictors of cardiovascular disease [1-6] and lung cancer [7-12] in People Living with HIV (PLHIV). In fact, in the antiretroviral era, smoking may contribute to a greater loss of life in PLHIV than HIV itself [9, 13]. In a Danish cohort of PLHIV, 12.3 (95%CI, 8.1-16.4) life years were lost in association with smoking compared to only 5.1 (95%CI, 1.6-8.5) life years lost in association with HIV . In addition, smoking rates are high in PLHIV, with studies reporting 21-84% of individuals being current smokers (vs. 19% in the general population) and 9-30% being former smokers [14-21]. In PLHIV, higher rates of un-employment, substance abuse, low education, lone-liness, depression, and food insecurity have all been associated with smoking or not being ready to quit [2, 22-24].
Smoking is a major modifiable health risk factor that, if addressed effectively, could drastically improve the health of PLHIV. Smokers living with HIV who abstain from tobacco smoking for more than a year are at lower risk of acquiring AIDS-defining illnesses, cardiovascular events, non-AIDS-defining malignancies, and bacterial pneumonia [12, 25-27]. We described the tobacco-related clinical and sociod-emographic characteristics of a convenience sample of tobacco smokers at the Chronic Viral Illness Service (CVIS), a tertiary HIV clinic in Montreal. We conducted an exploratory analysis of smoking cessation methods to identify potential areas of improvement in the clinic’s approach to smoking cessation.
The CVIS follows approximately 2,000 PLHIV and provides multi-disciplinary care for adult patients with chronic illnesses such as HIV and HCV. The clinic is located within the McGill University Health Centre (MUHC), a large public tertiary care hospital. Inclusion criteria for this study were patients with 1) HIV infection; 2) self-reported current tobacco smoking; 3) appoint-ments at the CVIS for clinical care; and 4) the ability to read and understand French or English. Self-reported non-smokers or former smokers were excluded from this study. This study was approved by the MUHC Research Ethics Board.
2.1. Data Collection
A convenience sample of tobacco smoking PLHIV with clinical care appointments at the CVIS was recruited from April to September 2017 to complete a 10-minute questionnaire on tobacco-related behaviours and out-comes. An on-site study coordinator (BL) notified care providers when one of their patients had a history of tobacco smoking (identified in weekly reviews of the clinical database) and encouraged referral of additional patients meeting study criteria.
Questionnaires were self-administered by patients or administered orally by study staff as needed. The questionnaire contained a combination of scales from a Papadakis et al. study and additional questions relevant to tobacco smoking in PLHIV . Questions about cigarette use, smoking-related symptomatology, previous cessation attempts, marijuana and e-cigarette use, and readiness to quit were included in the questionnaire. Written informed consent was obtained prior to survey completion. No compensation was provided. Additional information, such as Hepatitis C (HCV) coinfection, HIV-infection risk category, and sociodemographic data were collected through chart review.
2.2. Statistical Analysis
Analyses were conducted using R statistical software. Survey responses and participant characteristics are summarized using descriptive statistics. Differences in use of smoking cessation aids are compared using McNemar’s exact test, with a Bonferroni correction to account multiple testing (p-value cut-off of 0.01 for n=5 tests).
A total of 72 PLHIV participated in this study. The characteristics of the sample are summarized in Table 1. Most participants were men (83.3%) and/or HIV mono-infected (59.7%). The most common HIV transmission risk categories were Men who have Sex with Men (MSM) (40.3%) and People Who Inject Drugs (PWID) (38.9%).
|–||Study population||CVIS clinic|
|Age, years (median [IQR])||51 [43, 57]||52 [44, 59]|
|Sex (%)||Female||12 (16.7%)||486 (31.7%)|
|Male||60 (83.3%)||1047 (68.3%)|
|Infection Type (%)||HIV mono-infected||43 (59.7%)||1363 (88.9%)|
|HIV/HCV co-infected||29 (40.3%)||170 (11.1%)|
|HIV transmission risk-factors (%)||MSM||29 (40.3%)||470 (30.7%)|
|PWID||28 (38.9%)||104 (6.8%)|
|Endemic country||8 (11.1%)||347 (22.6%)|
|Heterosexual/Other||12 (16.7%)||419 (27.3%)|
|Lowest recorded CD4* (median [IQR])||533 [341.5, 702.5]||529 [355, 728]|
|Highest recorded VL* (median [IQR])||<40 [<40, <40]||<40 [<40, <40]|
|Detectable VL* (%)||17 (23.6%)||245 (16.0%)|
A summary of questionnaire responses is provided in Table 2. Half of the participants (51.4%) were followed by an allied health professional, such as a social worker or psychologist. Participants smoked a median of 330 cigarettes (or about 13 packs) per month and started smoking at a median age of 20 years. About half of the participants (47.3%) reported having their first cigarette of the day within the first 30 minutes of waking. Smoking to reduce stress appeared to be the most common reason for smoking (56.9%), followed by smoking for pleasure (51.4%) and smoking to reduce anxiety (45.8%). Two-thirds of participants (67.6%) reported that they would like to quit within the next six months and a similar number (65.3%) indicated they were interested in a clinical trial on smoking cessation. About half of the participants (55.6%) had smoked marijuana in the previous six months.
|Followed by an allied health professional (%)||37 (51.4%)|
|Age started smoking (median [IQR])||20 [14, 27]|
|Number of cigarettes per month (median [IQR])||330 [150, 600]|
|Reasons for smoking tobacco (%)||Reduce stress||41 (56.9%)|
|Reduce anxiety||33 (45.8%)|
|Social reasons||23 (31.9%)|
|Weight control/appetite suppression||8 (11.1%)|
|No reason provided||3|
|From waking, time to first cigarette (%)||Within 5 minutes||22 (30.6%)|
|6-30 minutes||12 (16.7%)|
|31-60 minutes||14 (19.4%)|
|After 60 minutes||24 (33.3%)|
|Symptoms (%)||Cough||28 (38.9%)|
|Phlegm or mucous||29 (40.3%)|
|Shortness of breath from mild exertion||43 (60.6%)|
|Ever made a quit attempt (%)||63 (87.5%)|
|Number of quit attempts (median [95%CI])||3 [1, 4]|
|Smoking cessation methods used (%)||Patch||36 (50.0%)|
|Oral therapy*||12 (16.7%)|
|“Nicotine gum or tablets”||8|
|No method provided||5|
|Feelings about quitting smoking (%)||I would like to quit in the next 30 days||22 (31.0%)|
|I would like to quit in the next six months||26 (36.6%)|
|I am not planning on quitting in the next six months||23 (32.4%)|
|Confidence in ability to quit smoking, 0-10 (median [IQR])||5.5 [3.0, 8.0]|
|Smoked marijuana in the past six months (%)||40 (55.6%)|
||3.5 [1.0, 19.2]|
|Ever used e-cigarettes (%)||7 (9.7%)|
|Self-reported smoking-related illnesses (%)||Heart disease, stroke or heart failure||3 (4.2%)|
|Depression or anxiety||30 (41.7%)|
|Interested in a clinical trial on smoking cessation (%)||47 (65.3%)|
The results of each McNemar’s test are summarized in Table 3. Among the 63 participants who had ever made a quit attempt (87.5%), both oral therapy (e.g. varenicline or bupropion) (16.7%) and smoking cessation counseling (5.6%) were used less than either nicotine patches (50.0%) or ‘other’ methods (50.0%), which included abstinence and/or nicotine gum.
The current study describes the smoking experience in a clinical sample of PLHIV and highlights some potential shortcomings in the CVIS’s strategy to smoking cessation.
Although two-thirds of the participants in our sample expressed an interest in quitting within six months, access to the majority of effective smoking cessation methods was relatively low. Half of the study participants (50.0%) had ever used nicotine patches to quit smoking, making Nicotine Replacement Therapy (NRT) the most frequently used smoking cessation aid. While this finding indicates that NRT is accessible to many participants, it could also suggest that NRT may not be optimally prescribed or administered to this group. Studies in PLHIV have found that compliance with NRT tends to be poor [29-32].
|Oral therapy vs. counseling||p=0.077|
|Oral therapy vs. nicotine patches||p<0.001|
|Oral therapy vs. ‘other’||p<0.001|
|Counseling vs. nicotine patches||p<0.001|
|Counseling vs. ‘other’||p<0.001|
Counselling and oral therapy were underutilized evidence-based smoking cessation strategies in our sample. Only 12 (16.7%) participants had ever tried oral therapy to quit smoking and only 4 (5.6%) had ever received counselling to quit smoking. In the general population, bupropion nearly doubles the odds of abstinence at 12 months compared to placebo (OR 1.85, 95% CI 1.63-2.10) and varenicline nearly triples the odds (OR 2.89, 95% CI 2.40-3.48), whereby the abstinence rate of control participants is about 10% . Few Randomized Controlled Trials (RCTs) have been conducted in PLHIV, but these treatments appear to be efficacious and well-tolerated . Similarly, a recent RCT of 248 PLHIV in France found that quit rates with varenicline were higher than the standard of care alone (OR 2.5, 95% CI: 1.0 to 6.1) .
Smoking cessation counselling is another effective intervention used in the general population, with increased relative quit rates of 1.39 (95%CI: 1.24 to 1.57) and 1.98 (95%CI: 1.60 to 2.46) for individual and group counselling, respectively . Studies of smoking cessation counseling in PLHIV have been hindered by methodological issues such as small sample sizes or lack of randomization . However, they appear to demonstrate a positive, albeit modest, effect . In clinics with a multi-disciplinary model of HIV care, such as the CVIS, there is potential for smoking cessation counselling to be delivered along side other types of counselling, in conjunction with optimally dosed NRT or oral therapy. Indeed, combined counselling and phar-macological smoking cessation interventions are effective in PLHIV, with quit rates ranging from 11.8 to 28% . In RCTs involving the general population, quit rates at three to six months ranged from 10% to 36.8% for counselling plus pharmacotherapy compared to 3.3 to 10.3% for phar-macotherapy alone . Early evidence suggests that these rates could be further improved if paired with concurrent treatment for depressive symptoms, which are highly prevalent in our sample [35, 36]. For example, in a recent RCT of PLHIV, combined NRT and cognitive behavioural therapy for smoking cessation and dep-ression/anxiety resulted in a 46% quit rate at six months, significantly higher than the 5% quit rate for NRT alone .
Our study had several limitations. Firstly, we were only able to recruit a limited number of participants, which hindered our ability to conduct more in-depth analyses. Secondly, given time and financial constraints, patients were recruited by convenience sampling, with many coming from the Canadian Coinfection Cohort and from the clinic outreach nurse . Thus, our sample is dissimilar from the general pool of HIV positive patients and likely a non-representative subset of smokers at the CVIS, consisting of more HCV-seropositive persons and more individuals followed by an allied health professional who may have more social or psychological needs than the overall pool of smokers in our clinic. This is supported by the descriptive statistics of CVIS patients provided in Table 1. Notably, 39% of our sample was PWID and 40.3% were HCV co-infected, while only 7% and 11.1% of CVIS patients with visits during the study period were PWID or HCV co-infected, respectively. There is currently no systematic identification of tobacco smoking patients at the clinic, which hinders our ability to assess the comparability of our sample with the general pool of tobacco smokers. This may limit the generalizability of our findings. We also did not collect any information about educational or financial char-acteristics of participants, pain, healthcare provider attitudes and/or practices, or timing of smoking cessation interventions, all of which are important factors for smoking cessation [2, 33, 38-43].
Our findings suggest the need for further research to determine and address barriers to smoking cessation and access to effective smoking cessation aids in PLHIV. Future studies might consider factors that affect moti-vation to quit, such as co-morbid mental health and substance use disorders, or the attitudes of HIV health-care providers.
This study was funded by Astra Zeneca Inc. and the McGill Department of Medicine. C. Costiniuk and B. Lebouché hold FRQ-S Junior 1 salary awards. B. Lebouché holds a CIHR SPOR Mentorship Chair in Innovative Clinical Trials. JP. Routy holds the McGill University Louis Lowenstein Chair in Hematology & Oncology. The funding institutions played no role in the design, collection, analysis, and interpretation of data.
ETHICS APPROVAL AND CONSENT TO PARTICIPATE
Approval was obtained by the Ethics Committee at the McGill University Health Centre (2017-2994), who reviewed and monitored this study.
HUMAN AND ANIMAL RIGHTS
No animals/humans were used for studies that are the basis of this research.
CONSENT FOR PUBLICATION
Written informed consent was obtained prior to survey completion.
CONFLICT OF INTEREST
The authors declare no conflict of interest, financial or otherwise.
We wish to acknowledge all the CVIS patients who took the time to complete this questionnaire, as well as the staff who referred participants.
|||Rasmussen LD, Helleberg M, May MT, et al. Myocardial infarction among Danish HIV-infected individuals: population-attributable fractions associated with smoking. Clin Infect Dis 2015; 60(9): 1415-23.
|||Rahmanian S, Wewers ME, Koletar S, Reynolds N, Ferketich A, Diaz P. Cigarette smoking in the HIV-infected population. Proc Am Thorac Soc 2011; 8(3): 313-9.
|||De P, Farley A, Lindson N, Aveyard P. Systematic review and meta-analysis: influence of smoking cessation on incidence of pneumonia in HIV. BMC Med 2013; 11(1): 15.
|||Armah KA, McGinnis K, Baker J, et al. HIV status, burden of comorbid disease, and biomarkers of inflammation, altered coagulation, and monocyte activation. Clin Infect Dis 2012; 55(1): 126-36.
|||Petrosillo N, Cicalini S. Smoking and HIV: Time for a change? BMC Med 2013; 11(1): 16.
|||van Zyl Smit RN, Pai M, Yew W-W, et al. Global lung health: the colliding epidemics of tuberculosis, tobacco smoking, HIV and COPD. Eur Respir J 2010; 35(1): 27-33.
|||Sigel K, Makinson A, Thaler J. Lung cancer in persons with HIV. Curr Opin HIV AIDS 2017; 12(1): 31-8.
|||Jackson-Morris A, Fujiwara PI, Pevzner E. Clearing the smoke around the TB-HIV syndemic: smoking as a critical issue for TB and HIV treatment and care. Int J Tuberc Lung Dis 2015; 19(9): 1003-6.
|||Helleberg M, Afzal S, Kronborg G, et al. Mortality attributable to smoking among HIV-1-infected individuals: A nationwide, population-based cohort study. Clin Infect Dis 2013; 56(5): 727-34.
|||Godbole SV, Nandy K, Gauniyal M, et al. HIV and cancer registry linkage identifies a substantial burden of cancers in persons with HIV in India. Medicine (Baltimore) 2016; 95(37): e4850.
|||Altekruse SF, Shiels MS, Modur SP, et al. Cancer burden attributable to cigarette smoking among HIV-infected people in North America. AIDS 2018; 32(4): 513-21.
|||Shepherd L, Ryom L, Law M, Petoumenos K, Hatleberg CI. Cessation of cigarette smoking and the impact on cancer incidence in human immunodeficiency virus–infected persons: The data collection on adverse events of Anti-HIV drugs study. 2018.|
|||Reddy KP, Parker RA, Losina E, et al. Impact of cigarette smoking and smoking cessation on life expectancy among people with HIV: A US-based modeling study. J Infect Dis 2016; 214(11): 1672-81.
|||Drummond MB, Merlo CA, Astemborski J, et al. The effect of HIV infection on longitudinal lung function decline among IDUs: A prospective cohort. AIDS 2013; 27(8): 1303-11.
|||Cui Q, Carruthers S, McIvor A, Smaill F, Thabane L, Smieja M. Effect of smoking on lung function, respiratory symptoms and respiratory diseases amongst HIV-positive subjects: a cross-sectional study. AIDS Res Ther 2010; 7(1): 6.
|||George MP, Kannass M, Huang L, Sciurba FC, Morris A. Respiratory symptoms and airway obstruction in HIV-infected subjects in the HAART era. PLoS One 2009; 4(7): e6328.
|||Gingo MR, George MP, Kessinger CJ, et al. Pulmonary function abnormalities in HIV-infected patients during the current antiretroviral therapy era. Am J Respir Crit Care Med 2010; 182(6): 790-6.
|||Madeddu G, Fois AG, Calia GM, et al. Chronic obstructive pulmonary disease: An emerging comorbidity in HIV-infected patients in the HAART era? Infection 2013; 41(2): 347-53.
|||Kristoffersen US, Lebech AM, Mortensen J, Gerstoft J, Gutte H, Kjaer A. Changes in lung function of HIV-infected patients: A 4.5-year follow-up study. Clin Physiol Funct Imaging 2012; 32(4): 288-95.
|||Hirani A, Cavallazzi R, Vasu T, et al. Prevalence of obstructive lung disease in HIV population: A cross sectional study. Respir Med 2011; 105(11): 1655-61.
|||Health Trends [Internet]. Statistics Canada. 2014 [cited January 21, 2018]; Available from: http://www12.statcan.gc.ca/ health-sante/82-213/index.cfm?Lang=ENG|
|||Regan S, Meigs JB, Grinspoon SK, Triant VA. Determinants of smoking and quitting in HIV-Infected Individuals. PLoS One 2016; 11(4): e0153103.
|||Stanton CA, Moadel AB, Kim RS, Weinberger AH, Shuter J. Loneliness in HIV-infected smokers. AIDS Care 2015; 27(2): 268-72.
|||Kim JE, Flentje A, Tsoh JY, Riley ED. Cigarette Smoking among Women Who Are Homeless or Unstably Housed: Examining the Role of Food Insecurity. J Urban Health 2017; 94(4): 514-24.
|||Lifson AR, Neuhaus J, Arribas JR, van den Berg-Wolf M, Labriola AM, Read TR. Smoking-related health risks among persons with HIV in the Strategies for Management of Antiretroviral Therapy clinical trial. Am J Public Health 2010; 100(10): 1896-903.
|||Bénard A, Mercié P, Alioum A, et al. Bacterial pneumonia among HIV-infected patients: decreased risk after tobacco smoking cessation. ANRS CO3 Aquitaine Cohort, 2000-2007. PLoS One 2010; 5(1): e8896.
|||Fuster M, Estrada V, Fernandez-Pinilla MC, et al. Smoking cessation in HIV patients: rate of success and associated factors. HIV Med 2009; 10(10): 614-9.
|||Papadakis S, Tulloch HE, Gharib M, Pipe AL. Profile of tobacco users identified in primary care practice and predictors of readiness to quit: a cross-sectional survey. CMAJ Open 2016; 4(1): E41-7.
|||Ledgerwood DM, Yskes R. Smoking cessation for people living with HIV/AIDS: a literature review and synthesis. Nicotine Tob Res 2016; 18(12): 2177-84.
|||Ingersoll KS, Cropsey KL, Heckman CJ. A test of motivational plus nicotine replacement interventions for HIV positive smokers. AIDS Behav 2009; 13(3): 545-54.
|||Tucker JS, Shadel WG, Galvan FH, Naranjo D, Lopez C, Setodji C. Pilot evaluation of a brief intervention to improve nicotine patch adherence among smokers living with HIV/AIDS. Psychol Addict Behav 2017; 31(2): 148-53.
|||Matthews AK, Conrad M, Kuhns L, Vargas M, King AC. Project Exhale: preliminary evaluation of a tailored smoking cessation treatment for HIV-positive African American smokers. AIDS Patient Care STDS 2013; 27(1): 22-32.
|||Reid RD, Pritchard G, Walker K, Aitken D, Mullen K-A, Pipe AL. Managing smoking cessation. CMAJ 2016; 188(17-18): E484-92.
|||Mercié P, Arsandaux J, Katlama C, et al. Efficacy and safety of varenicline for smoking cessation in people living with HIV in France (ANRS 144 Inter-ACTIV): a randomised controlled phase 3 clinical trial. Lancet HIV 2018; 5(3): e126-35.
|||Balfour L, Wiebe SA, Cameron WD, et al. An HIV-tailored quit-smoking counselling pilot intervention targeting depressive symptoms plus Nicotine Replacement Therapy. AIDS Care 2017; 29(1): 24-31.
|||OʼCleirigh C, Zvolensky MJ, Smits JAJ, et al. Integrated Treatment for Smoking Cessation, Anxiety, and Depressed Mood in People Living With HIV: A Randomized Controlled Trial. J Acquir Immune Defic Syndr 2018; 79(2): 261-8.
|||Klein MB, Saeed S, Yang H, et al. Cohort profile: the Canadian HIV-hepatitis C co-infection cohort study. Int J Epidemiol 2010; 39(5): 1162-9.
|||Vidrine DJ, Frank SG, Savin MJ, Waters AJ, Li Y, Chen S, et al. HIV Care Initiation: A Teachable Moment for Smoking Cessation? Nicotine Tob Res 2017.
|||Mussulman LM, Faseru B, Fitzgerald S, Nazir N, Patel V, Richter KP. A randomized, controlled pilot study of warm handoff versus fax referral for hospital-initiated smoking cessation among people living with HIV/AIDS. Addict Behav 2018; 78: 205-8.
|||Stead LF, Buitrago D, Preciado N, Sanchez G, Hartmann-Boyce J, Lancaster T. Physician advice for smoking cessation. Cochrane Database Syst Rev 2013; (5): CD000165.
|||Calvo-Sánchez M, Martinez E. How to address smoking cessation in HIV patients. HIV Med 2015; 16(4): 201-10.
|||Tesoriero JM, Gieryic SM, Carrascal A, Lavigne HE. Smoking among HIV positive New Yorkers: prevalence, frequency, and opportunities for cessation. AIDS Behav 2010; 14(4): 824-35.
|||Aigner CJ, Gritz ER, Tamí-Maury I, Baum GP, Arduino RC, Vidrine DJ. The role of pain in quitting among human immunodeficiency virus (HIV)-positive smokers enrolled in a smoking cessation trial. Subst Abus 2017; 38(3): 249-52.